Glucagaon-like peptide (GLP-1) and Adipose Tissue Inflammation in Obesity Study

Effect of glucagon-like peptide infusion on systemic and adipose tissue inflammation in obese people.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12614000799651

Acronym

GATIO

Enrollment

Registered

2014-07-28

Start date

2015-03-11

Completion date

2016-03-30

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

One of the risk factors for developing diabetes and cardiovascular disease (heart attacks and stroke) is obesity. We think that one of the reasons that obesity increases this risk is because there is increased production of inflammatory molecules such as interleukin-6 (IL-6) and tumor necrosis factor-a, in fat (adipose) tissue. These inflammatory molecules may damage blood vessels and reduce the effectiveness of the body’s glucose regulating hormone called insulin. A hormone called glucogon-like peptide-1 (GLP-1) that is released from the gut early after intake of food, is thought to decrease inflammation. However, there is little known about the effect of GLP-1 on inflammation in adipose tissue. Our previous research has shown that levels of IL-6 in the blood decrease early after ingestion of food. This decrease in IL-6 levels might be due to an increase in GLP-1 levels in the blood after a meal. The aim of our study is to determine the effect of GLP-1 infusion on adipose tissue inflammation and plasma concentrations of IL-6 and other inflammatory molecules in obese people.

Interventions

Arm1. Intravenous infusion of glucagon-like peptide (GLP-1) at a dose of 0.9 pmol/kg/min. The GLP-1 will be obtained from Bachem AG in sealed vials (Clinalfa). The GLP-1 will be infused for 240 min into fasted individuals in the early morning. Plasma concentrations of GLP-1 will be measured. Arm2. Infusion of 0.9% saline as a control. There will be a 3 week washout period between treatments in an individual to prevent carryover from one treatment to the next.

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used) (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

Body mass index>30 kg/m2

Exclusion criteria

Diabetes, cigarette smoking, malignancies, cardiac and vascular diseases, uncontrolled hypertension, psychiatric disorders, previous significant abdominal surgery, medications which affect inflammation or glucose metabolism

Outcome results